Cargando…
The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels
AIMS/HYPOTHESIS: Many individuals who develop type 2 diabetes also display increased glucagon levels (hyperglucagonaemia), which we have previously found to be associated with the metabolic syndrome. The concept of a liver–alpha cell axis provides a possible link between hyperglucagonaemia and eleva...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864806/ https://www.ncbi.nlm.nih.gov/pubmed/33275161 http://dx.doi.org/10.1007/s00125-020-05334-x |
_version_ | 1783647723037130752 |
---|---|
author | Gar, Christina Haschka, Stefanie J. Kern-Matschilles, Stefanie Rauch, Barbara Sacco, Vanessa Prehn, Cornelia Adamski, Jerzy Seissler, Jochen Wewer Albrechtsen, Nicolai J. Holst, Jens J. Lechner, Andreas |
author_facet | Gar, Christina Haschka, Stefanie J. Kern-Matschilles, Stefanie Rauch, Barbara Sacco, Vanessa Prehn, Cornelia Adamski, Jerzy Seissler, Jochen Wewer Albrechtsen, Nicolai J. Holst, Jens J. Lechner, Andreas |
author_sort | Gar, Christina |
collection | PubMed |
description | AIMS/HYPOTHESIS: Many individuals who develop type 2 diabetes also display increased glucagon levels (hyperglucagonaemia), which we have previously found to be associated with the metabolic syndrome. The concept of a liver–alpha cell axis provides a possible link between hyperglucagonaemia and elevated liver fat content, a typical finding in the metabolic syndrome. However, this association has only been studied in individuals with non-alcoholic fatty liver disease. Hence, we searched for a link between the liver and the alpha cells in individuals with non-steatotic levels of liver fat content. We hypothesised that the glucagon–alanine index, an indicator of the functional integrity of the liver–alpha cell axis, would associate with liver fat and insulin resistance in our cohort of women with low levels of liver fat. METHODS: We analysed data from 79 individuals participating in the Prediction, Prevention and Subclassification of Type 2 Diabetes (PPSDiab) study, a prospective observational study of young women at low to high risk for the development of type 2 diabetes. Liver fat content was determined by MRI. Insulin resistance was calculated as HOMA-IR. We conducted Spearman correlation analyses of liver fat content and HOMA-IR with the glucagon–alanine index (the product of fasting plasma levels of glucagon and alanine). The prediction of the glucagon–alanine index by liver fat or HOMA-IR was tested in multivariate linear regression analyses in the whole cohort as well as after stratification for liver fat content ≤0.5% (n = 39) or >0.5% (n = 40). RESULTS: The glucagon–alanine index significantly correlated with liver fat and HOMA-IR in the entire cohort (ρ = 0.484, p < 0.001 and ρ = 0.417, p < 0.001, respectively). These associations resulted from significant correlations in participants with a liver fat content >0.5% (liver fat, ρ = 0.550, p < 0.001; HOMA-IR, ρ = 0.429, p = 0.006). In linear regression analyses, the association of the glucagon–alanine index with liver fat remained significant after adjustment for age and HOMA-IR in all participants and in those with liver fat >0.5% (β = 0.246, p = 0.0.23 and β = 0.430, p = 0.007, respectively) but not in participants with liver fat ≤0.5% (β = −0.184, p = 0.286). CONCLUSIONS/INTERPRETATION: We reproduced the previously reported association of liver fat content and HOMA-IR with the glucagon–alanine index in an independent study cohort of young women with low to high risk for type 2 diabetes. Furthermore, our data indicates an insulin-resistance-independent association of liver fat content with the glucagon–alanine index. In summary, our study supports the concept that even lower levels of liver fat (from 0.5%) are connected to relative hyperglucagonaemia, reflecting an imminent impairment of the liver–alpha cell axis. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-020-05334-x. |
format | Online Article Text |
id | pubmed-7864806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78648062021-02-16 The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels Gar, Christina Haschka, Stefanie J. Kern-Matschilles, Stefanie Rauch, Barbara Sacco, Vanessa Prehn, Cornelia Adamski, Jerzy Seissler, Jochen Wewer Albrechtsen, Nicolai J. Holst, Jens J. Lechner, Andreas Diabetologia Article AIMS/HYPOTHESIS: Many individuals who develop type 2 diabetes also display increased glucagon levels (hyperglucagonaemia), which we have previously found to be associated with the metabolic syndrome. The concept of a liver–alpha cell axis provides a possible link between hyperglucagonaemia and elevated liver fat content, a typical finding in the metabolic syndrome. However, this association has only been studied in individuals with non-alcoholic fatty liver disease. Hence, we searched for a link between the liver and the alpha cells in individuals with non-steatotic levels of liver fat content. We hypothesised that the glucagon–alanine index, an indicator of the functional integrity of the liver–alpha cell axis, would associate with liver fat and insulin resistance in our cohort of women with low levels of liver fat. METHODS: We analysed data from 79 individuals participating in the Prediction, Prevention and Subclassification of Type 2 Diabetes (PPSDiab) study, a prospective observational study of young women at low to high risk for the development of type 2 diabetes. Liver fat content was determined by MRI. Insulin resistance was calculated as HOMA-IR. We conducted Spearman correlation analyses of liver fat content and HOMA-IR with the glucagon–alanine index (the product of fasting plasma levels of glucagon and alanine). The prediction of the glucagon–alanine index by liver fat or HOMA-IR was tested in multivariate linear regression analyses in the whole cohort as well as after stratification for liver fat content ≤0.5% (n = 39) or >0.5% (n = 40). RESULTS: The glucagon–alanine index significantly correlated with liver fat and HOMA-IR in the entire cohort (ρ = 0.484, p < 0.001 and ρ = 0.417, p < 0.001, respectively). These associations resulted from significant correlations in participants with a liver fat content >0.5% (liver fat, ρ = 0.550, p < 0.001; HOMA-IR, ρ = 0.429, p = 0.006). In linear regression analyses, the association of the glucagon–alanine index with liver fat remained significant after adjustment for age and HOMA-IR in all participants and in those with liver fat >0.5% (β = 0.246, p = 0.0.23 and β = 0.430, p = 0.007, respectively) but not in participants with liver fat ≤0.5% (β = −0.184, p = 0.286). CONCLUSIONS/INTERPRETATION: We reproduced the previously reported association of liver fat content and HOMA-IR with the glucagon–alanine index in an independent study cohort of young women with low to high risk for type 2 diabetes. Furthermore, our data indicates an insulin-resistance-independent association of liver fat content with the glucagon–alanine index. In summary, our study supports the concept that even lower levels of liver fat (from 0.5%) are connected to relative hyperglucagonaemia, reflecting an imminent impairment of the liver–alpha cell axis. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains peer-reviewed but unedited supplementary material available at 10.1007/s00125-020-05334-x. Springer Berlin Heidelberg 2020-12-04 2021 /pmc/articles/PMC7864806/ /pubmed/33275161 http://dx.doi.org/10.1007/s00125-020-05334-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Gar, Christina Haschka, Stefanie J. Kern-Matschilles, Stefanie Rauch, Barbara Sacco, Vanessa Prehn, Cornelia Adamski, Jerzy Seissler, Jochen Wewer Albrechtsen, Nicolai J. Holst, Jens J. Lechner, Andreas The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
title | The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
title_full | The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
title_fullStr | The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
title_full_unstemmed | The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
title_short | The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
title_sort | liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864806/ https://www.ncbi.nlm.nih.gov/pubmed/33275161 http://dx.doi.org/10.1007/s00125-020-05334-x |
work_keys_str_mv | AT garchristina theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT haschkastefaniej theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT kernmatschillesstefanie theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT rauchbarbara theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT saccovanessa theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT prehncornelia theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT adamskijerzy theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT seisslerjochen theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT weweralbrechtsennicolaij theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT holstjensj theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT lechnerandreas theliveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT garchristina liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT haschkastefaniej liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT kernmatschillesstefanie liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT rauchbarbara liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT saccovanessa liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT prehncornelia liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT adamskijerzy liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT seisslerjochen liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT weweralbrechtsennicolaij liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT holstjensj liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels AT lechnerandreas liveralphacellaxisassociateswithliverfatandinsulinresistanceavalidationstudyinwomenwithnonsteatoticliverfatlevels |